|Videos|December 22, 2019
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
Author(s)Sponsored Content
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on CURE
1
Doctor Outlines Cervical Cancer Care, Side Effects, HPV Prevention
2
FDA to Review New Drug Combo for Previously Treated Metastatic Colorectal Cancer
3
Erleada Shows Survival Advantage in Real-World Study of Metastatic Prostate Cancer
4
Expert Insights: FDA Approval of Lymphir for Cutaneous T-Cell Lymphoma
5